THE EFFICACY OF CGRP ANTAGONISTS IN THE TREATMENT OF MIGRAINE  (Review Article)

ZAHEER AALIF; AKHTAR OMAR; RAVI NARENDRANATH; MOHAMMED BILAL MUNEER; TAMAR AKHVLEDIANI

doi:10.52340/jecm.2022.02.22

THE EFFICACY OF CGRP ANTAGONISTS IN THE TREATMENT OF MIGRAINE (Review Article)

Authors

ZAHEER AALIF
AKHTAR OMAR
RAVI NARENDRANATH
MOHAMMED BILAL MUNEER
TAMAR AKHVLEDIANI

DOI:

https://doi.org/10.52340/jecm.2022.02.22

Abstract

Migraine is one of the most common and disabling diseases in the world. The usage of Calcitonin Gene-Related Peptide (CGRP) antagonist drugs has been on the horizon and looks to be a promising treatment option. Growing evidence suggests that CGRP plays a key role in the development of peripheral sensitization and associated enhanced pain. CGRP is involved in the development of neurogenic inflammation and is upregulated in inflammatory and neuropathic pain conditions. Drugs like Erenumab, Rimegepant, Olcegepant and others of the same category have shown significantly fewer side effects along with high therapeutic effects, which makes this group of drugs a useful addition to the existing therapeutic options.

Downloads

Download data is not yet available.

References

Andreou AP. et al. Activation of iGluR5 Kainate Receptors Inhibits Neurogenic Dural Vasodilatation in an Animal Model of Trigeminovascular Activation. Br J Pharmacol Blackwell Publishing Ltd, 2009;157:464–73

Chan C, Wei D, Goadsby PJ. Biochemical Modulation and Pathophysiology of Migraine; J Neuroophthalmol 2019;39(4):470-79

Deen M, Correnti E, Kamm K. et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18(1):96.

Durham PL. CGRP-Receptor Antagonists — A Fresh Approach to Migraine Therapy? N Engl J Med 2004; 350(11):1073–75.

Goadsby PJ. Pathophysiology of Migraine. Ann Indian AcadNeurol2012; 15 (Suppl 1): S15–S22.

Goadsby PJ, Edvinsson L, Ekman R. Release of Vasoactive Peptides in the Extracerebral Circulation of Humans and the Cat during Activation of the Trigeminovascular System. Ann Neu1988;23(2):193-96;

Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 2017; 377(22):2123–32

Ho TW,Edvinsson L, Goadsby PJ. et al. CGRP and Its Receptors Provide New Insights into Migraine Pathophysiology. Nat RevNeurol 2010; 6:573–82

Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. N Engl J Med 2004; 350(11):1104–10.

Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev PharmacolToxicol 2015; 55:533–52.

Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16(2):69–75.